It is a great privilege to present the 39th Annual Wendell Hughes Lecture. Nearly all of the previous honorees have focused on technical aspects of oculoplastic surgery or the curious collection of diseases and dysfunctions that, when cobbled together, constitute our unique subspecialty. So, when given the opportunity to share a few thoughts from this podium, my first instinct was to comment on one of the clinical topics such as Graves ophthalmopathy or orbital tumors that have intrigued me over the years. But I would have little new to share with this audience given that my focus over the past several years has been on budgets rather than Botox, regulations rather than Restylane, liver transplants rather than orbital implants, hospital construction rather than Hughes reconstruction. Therefore, I decided to share a personal perspective on what I’ve observed as my career has migrated from the operating room to the board room.
Bartley GB. From the Operating Room to the Board Room: An Oculoplastic Surgeon's Perspective on Health Care in AmericaThe 2008 Wendell Hughes Lecture. Arch Ophthalmol. 2009;127(7):932–935. doi:10.1001/archophthalmol.2009.131